search
Back to results

Azacitidine and Homoharringtonine in JMML

Primary Purpose

JMML

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Azacitidine and homoharringtonine
Sponsored by
Air Force Military Medical University, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for JMML

Eligibility Criteria

1 Month - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Newly diagnosed JMML, with PB and BM confirming diagnosis prior to informed consent signature, with one of the following:

    1. somatic mutation in PTPN11
    2. somatic mutation in KRAS
    3. somatic mutation in NRAS and HbF % > 5x normal value for age
    4. clinical diagnosis of neurofibromatosis Type 1.

Exclusion Criteria:

  • 1. Any condition that would prevent the subject from participating in the study.

    2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if participated in the study.

    3. Any condition that confounds the ability to interpret data from the study.

Sites / Locations

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention group

Arm Description

Outcomes

Primary Outcome Measures

Juvenile Myelomonocytic Leukemia (JMML) response rate at end of 4 Months
Defined as proportion of patients with sustained clinical complete remission [cCR] or clinical partial remission [cPR] according to the International JMML response criteria in Niemeyer 2014 at 3 months (28 days cycles). Response must be sustained for at least 4 weeks either in the 4-week period preceding or succeeding 3 months (ie, sustained over the period minimum 2 months to end of 3 months, or end of 3 months to end of 4 months).

Secondary Outcome Measures

Full Information

First Posted
August 6, 2020
Last Updated
August 6, 2020
Sponsor
Air Force Military Medical University, China
Collaborators
Qilu Hospital of Shandong University, Taian City Central Hospital, The Affiliated Hospital of Qingdao University, The Second Hospital of Hebei Medical University, Children's Hospital of Hebei Province
search

1. Study Identification

Unique Protocol Identification Number
NCT04505995
Brief Title
Azacitidine and Homoharringtonine in JMML
Official Title
Efficacy of Concomitant Use of Azacitidine and Homoharringtonine in Children With Juvenile Myelomonocytic Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2020 (Actual)
Primary Completion Date
January 1, 2023 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Air Force Military Medical University, China
Collaborators
Qilu Hospital of Shandong University, Taian City Central Hospital, The Affiliated Hospital of Qingdao University, The Second Hospital of Hebei Medical University, Children's Hospital of Hebei Province

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in children with JMML. The primary objective is to assess the treatment effect on response rate in this subject population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
JMML

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention group
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Azacitidine and homoharringtonine
Intervention Description
Concommitant use of azacitidine and homoharringtonine
Primary Outcome Measure Information:
Title
Juvenile Myelomonocytic Leukemia (JMML) response rate at end of 4 Months
Description
Defined as proportion of patients with sustained clinical complete remission [cCR] or clinical partial remission [cPR] according to the International JMML response criteria in Niemeyer 2014 at 3 months (28 days cycles). Response must be sustained for at least 4 weeks either in the 4-week period preceding or succeeding 3 months (ie, sustained over the period minimum 2 months to end of 3 months, or end of 3 months to end of 4 months).
Time Frame
Up to 4 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Newly diagnosed JMML, with PB and BM confirming diagnosis prior to informed consent signature, with one of the following: somatic mutation in PTPN11 somatic mutation in KRAS somatic mutation in NRAS and HbF % > 5x normal value for age clinical diagnosis of neurofibromatosis Type 1. Exclusion Criteria: 1. Any condition that would prevent the subject from participating in the study. 2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if participated in the study. 3. Any condition that confounds the ability to interpret data from the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Wen-Yu Yang, M.D.
Phone
+86-22-23909138
Email
yangwenyu@ihcams.ac.cn
Facility Information:
Facility Name
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300020
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiao-Fan Zhu, M.D.
Phone
+86-22-23909001
Email
xfzhu@ihcams.ac.cn

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Azacitidine and Homoharringtonine in JMML

We'll reach out to this number within 24 hrs